Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Vor Biopharma ( (VOR) ).
Vor Biopharma Inc. announced promising clinical data from its Phase 1/2 VBP101 study, showing improved relapse-free survival in AML patients treated with trem-cel followed by Mylotarg. The study demonstrated effective engraftment and maintained blood counts, broadening Mylotarg’s therapeutic index. The FDA provided positive feedback on the study’s design, aligning on key aspects for future trials, signaling potential advancements in post-transplant therapies.
Learn more about VOR stock on TipRanks’ Stock Analysis page.
